2014
DOI: 10.1016/j.atherosclerosis.2014.02.004
|View full text |Cite
|
Sign up to set email alerts
|

Association of Lp-PLA2 with digital reactive hyperemia, coronary flow reserve, carotid atherosclerosis and arterial stiffness in coronary artery disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
40
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 40 publications
(42 citation statements)
references
References 38 publications
2
40
0
Order By: Relevance
“…Elevated cfPWV values are a risk factor for these disorders, suggesting a close relationship between large artery stiffness, reflected by cfPWV, and microvascular changes. In a recent publication by Ikonomidis and colleagues, arterial stiffness, quantified by pulse wave velocity, was identified as a valid marker of atherosclerosis and was associated with impaired coronary flow reserve and CAD.…”
Section: Discussionmentioning
confidence: 99%
“…Elevated cfPWV values are a risk factor for these disorders, suggesting a close relationship between large artery stiffness, reflected by cfPWV, and microvascular changes. In a recent publication by Ikonomidis and colleagues, arterial stiffness, quantified by pulse wave velocity, was identified as a valid marker of atherosclerosis and was associated with impaired coronary flow reserve and CAD.…”
Section: Discussionmentioning
confidence: 99%
“…When data were missing or results for continuous value of FMD or Ln_RHI were not reported, the original authors were contacted in an attempt to obtain these data. One study reported risk estimates for RHI . We contacted and asked the authors to transform RHI results to logarithmic value and obtained results with Ln_RHI.…”
Section: Methodsmentioning
confidence: 99%
“…The role of Lp-PLA 2 activity as a target for pharmaceutical intervention was cast in doubt after publication of the Integrated Biomarker and Imaging Study 2, a randomized placebo controlled phase II trial which found no benefit with the Lp-PLA 2 inhibitor darapladib in reducing major adverse cardiac events in patients with an ACS (21). Ikonomidis et al suggested a prognostic role for Lp-PLA 2 in chronic CAD subjects and attributed the same to potentially detrimental effects of the enzyme on endothelial function and arterial wall properties (22). Yang et al reported initial evidence of role of Lp-PLA 2 in endothelial dysfunction in an in vitro model of atherosclerosis, by regulating the expression of AMP-activated protein kinase (AMPK) that is a potential therapeutic target for improving endothelial function (23).…”
Section: Role Of Lp-pla 2 In Cadmentioning
confidence: 99%